BCL2L11 and neoplasm: ABT-263 relieves the inhibition of BCL-XL to BIM; hence, the MEK inhibitor-induced expression of the pro-apoptotic protein BIM increases cell apoptosis and reduces the tumour volume in KRAS mutant cancer models [63].